Microfluidics, producer of the Microfluidizer nanoparticle creation technology for the pharmaceutical, biotechnology, cosmetic and nutraceutical industries, today announced it has rebranded its technology as the PureNano platform.

The PureNano platform, featuring the PureNano Continuous Crystallizer, combines a unique machine with expert process development to create smaller and more consistent particle sizes than was previously possible. PureNano has numerous applications, especially within the pharmaceutical and energy industries.

“Pharmaceutical companies are seeking solutions for continuous crystallization using high shear, and PureNano fits this trend,” Mimi Panagiotou, Ph.D., Microfluidics chief technology officer and co-creator of the technology stated in the press release. “As a platform technology, PureNano opens new avenues for improving drug bioavailability, suspension stability and actives delivery for potential breakthrough applications.”

Microfluidics president and CEO Michael C. Ferrara said that beta units are surpassing expectations of the company’s pharmaceutical customers as the technology’s full potential continues to be revealed.

“PureNano is a milestone achievement of innovation for our company and represents a revolutionary and necessary step forward in the evolution of continuous crystallization,” Ferrara stated.

The PureNano/MRT technology is a globally patent-pending technology with active filings and applications in Australia, Canada, China, Europe, India, Israel, Japan and the United States.

For more information visit http://www.microfluidicscorp.com